MedTrace Logo

Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting

NCT04621461 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2021-02-11

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled trial to assess the efficacy of zinc in a higher risk COVID-19 positive outpatient population.

Conditions

  • Corona Virus Infection

Interventions

DIETARY_SUPPLEMENT

Zinc Sulfate 220 MG

220mg once daily for 5 days

DRUG

Placebo

Once daily for 5 days

Sponsors & Collaborators

  • St. Francis Hospital, New York

    lead OTHER

Principal Investigators

  • Avni Thakore, MD · St. Francis Hospital - The Heart Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-20
Primary Completion
2021-02-08
Completion
2021-02-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04621461 on ClinicalTrials.gov